Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and to reduce cardiovascular death

Sources

FDA label: Ozempic (semaglutide) injection, Novo Nordisk, revised 2024
SUSTAIN-6 cardiovascular outcomes trial: Marso SP et al., NEJM 2016
SUSTAIN-7 trial: Ahmann AJ et al., Diabetes Care 2018
SUSTAIN-10 trial: Capehorn MS et al., Diabetes Therapy 2020
FDA Drug Shortages Database, accessed January 2026
Novo Nordisk Savings Program terms, updated Q4 2025
CMS Medicare Part D coverage data, 2026 plan year

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.